Project Grant R01AR084689
Award Date
8/22/24
Completion Date
7/31/29
Dollars Obligated
$402K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
This Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $312,323 to Knoubis Bio Inc. to develop a novel bispecific biologic therapy for rheumatoid arthritis (RA). The project aims to target the transmembrane tyrosine phosphatase PTPRS and its extracellular ligand syndecan-4 to reduce synoviocyte invasiveness and inflammatory arthritis, providing...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
This $506,085 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The primary focus is on evaluating the potential of obesity-induced inflammatory mediators, including proteins (adipokines) and lipids, to predict...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $529,616.00 in funding to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Incorporated) to support research into the cellular mechanisms driving treatment failure in rheumatoid arthritis (RA). The key objectives of this 5-year project are to: 1)...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $553,248 to The Trustees of the University of Pennsylvania for research on INPP5E signaling and treatment approaches for rheumatoid arthritis (RA). The key objectives are to: 1) investigate how macrophage INPP5E expression impacts inflammation and bone erosion in RA, by analyzing...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $170,101 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, for a project titled "Dissecting the Spatial Heterogeneity of Synovial Inflammation in Rheumatoid Arthritis". The project aims to systematically characterize the spatial heterogeneity of synovial inflammation in rheumatoid...
This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Panorama Research Incorporated, doing business as Panorama Research Inc., a $275,765 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop an antibody-based therapy for reducing scarring and fibrosis following joint surgeries. The project aims to improve the delivery and tissue residence of a lead humanized antibody that inhibits collagen fibril formation, thereby...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $187,938 to The Johns Hopkins University to conduct research on the origin of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). The primary objectives are to investigate the hypothesis that ACPAs may arise from antibodies targeting structurally similar carbamylated proteins, which...